23:28 , Jul 13, 2018 |  BC Extra  |  Preclinical News

RXR a potential minimal residual disease target in melanoma

New research into the biology of solid tumor minimal residual disease (MRD) has revealed retinoid X receptor (RXR) as a potential target to delay development of drug resistance in melanoma. Cancer relapse is driven by...
08:00 , Dec 19, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Colon cancer Retinoid X receptor-g (RXRG; RXRg) In vitro and mouse studies suggest spironolactone or RXRg agonists could help treat colon cancer. In colon cancer...
08:00 , Jan 6, 2011 |  BC Innovations  |  Targets & Mechanisms

More mileage out of myelin

A team led by U.K. researchers has shown that retinoid X receptor agonists can enhance remyelination of demyelinated axons in rodents by increasing the differentiation of oligodendrocyte precursor cells into oligodendrocytes. 1 This remyelination activity...
08:00 , Dec 16, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Multiple sclerosis (MS) Retinoid X receptor-g (RXRG; RXRg) Patient sample and rodent studies suggest that RXR agonists could be used...
08:00 , Feb 9, 1998 |  BC Week In Review  |  Company News

INSERM other research news

French researchers published in Science the loss of dopamine function in mice mutated to lack various retinoid receptors in the brain. The knockout mice showed statistically significant reductions in standard movement tests of dopamine-mediated motor...